Implementing Molecular Diagnostics in Clinical Oncology

With the advent of NGS technologies, targeted immunotherapies, and biomarker-based interventions, clinical oncology is one of the areas of medicine with the highest potential impact for precision medicine approaches. New therapies and diagnostics offer great opportunities, but also raise significant questions regarding which tests to offer, how to integrate these into existing organizations and regular clinical practice, and how to ensure access to cutting-edge therapies while maintaining diagnostic safety and quality measures.

 As part of the BigMed project we aim to map out the organizational structures, processes, and systems that support molecular diagnostics for cancer at various institutions across the Nordics. By interviewing enough stakeholders from different institutions, we aim to describe common trends and generalized learnings. Our hope is that this work can give visibility to the shared challenges and paths forward that allow more effective molecular diagnostics and ultimately better cancer care. 

"Our goal is to (...) contribute to more effective molecular diagnostics, and ultimately better cancer care."

Information gathering

At each institution, we’re aiming at a 1-2 day series of interviews where we discuss processes, systems, organizations, and the patient/sample pathway. Based on this, we’ll document our notes and send out a process map and some follow-up questions to check for correctness. 

Goal

After gathering information from various stakeholders, our aim is to synthesize this into several key learnings and develop a report to be completed in 2020.  

A project like this is only possible if a broad range of participants are willing to take time out of their already-full schedules to share their knowledge and opinions. Our goal is to make sure these viewpoints are faithfully represented, and hopefully give some visibility to the common challenges and solutions that can contribute to more effective molecular diagnostics, and ultimately better cancer care. 

Status:

In progress

Partners:

DNV GL, Karolinska Institutet, Oslo Universitetssykehus

Topics

Bioinformatics,

Genomics

Courtney Nadeau

DNV GL

+47 458 47 325

Send email

Stephen McAdam

DNV GL

+47 908 22 616

Send email

Portrait of Stephen

Relevant Projects

Close up photo of test equipment in a lab

Benchmarking as a tool for quality in genetic testing

Ensuring accuracy in genomic medicineModern medical tests based on DNA and RNA sequencing are composed of a pipeline of numerous hardware systems, complex proprietary and open-source software, custom-built scripts, and manual,

Comprehensive clinical report from molecular diagnostics in cancer

Comprehensive clinical report from molecular diagnostics in cancer

Cancer is a genetic disease, as DNA is altered in each tumor. The changes differ greatly between different tumors and over time in a tumor. Many changes can occur in each tumor, and these changes may represent targets for therapy, or serve